Understanding how a protein called p21 activated kinase contributes to leukemia
Role of p21 activated kinase in Leukemogenesis
['FUNDING_R01'] · INDIANA UNIVERSITY INDIANAPOLIS · NIH-11135342
This research explores how certain cell pathways contribute to the development of myeloid leukemia, particularly in individuals with conditions like diabetes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INDIANA UNIVERSITY INDIANAPOLIS (nih funded) |
| Locations | 1 site (INDIANAPOLIS, UNITED STATES) |
| Trial ID | NIH-11135342 on ClinicalTrials.gov |
What this research studies
Our previous work identified new ways that specific cancer-causing genes, like FLT3ITD and KIT, lead to myeloid leukemias such as AML and MPNs. This current effort aims to better understand how particular cell pathways, including PI3Kinase/c-Myc/GCN2 and p38α MAPK, drive the early stages of leukemia development, known as clonal hematopoiesis, in pre-leukemic cells. We are especially interested in how these pathways interact with a common genetic change called the TET2 mutation, and how conditions like infection or high blood sugar (seen in diabetes) can speed up the progression to full-blown leukemia. By identifying these signaling mechanisms, we hope to uncover new targets for future treatments.
Who could benefit from this research
Good fit: This foundational research is relevant to patients with myeloid leukemias, such as AML and MPNs, and those with TET2 mutations or conditions like diabetes that may increase leukemia risk.
Not a fit: Patients without myeloid leukemias or related pre-leukemic conditions would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to prevent or treat myeloid leukemias, especially for patients with pre-existing conditions like diabetes.
How similar studies have performed: Previous work by this team has identified novel signaling pathways in leukemia, building a foundation for this current, more focused investigation into specific mechanisms.
Where this research is happening
INDIANAPOLIS, UNITED STATES
- INDIANA UNIVERSITY INDIANAPOLIS — INDIANAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAPUR, REUBEN — INDIANA UNIVERSITY INDIANAPOLIS
- Study coordinator: KAPUR, REUBEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus, Cancer Genes, Cancer-Promoting Gene, Cardiovascular Diseases